Cited by 1,036Treatment of Major DepressionNeuroscience and Neuropharmacology ResearchNeurotransmitter Receptor Influence on Behavior

Towards a glutamate hypothesis of depression

Open access
Sanacora, Gerard, Treccani, Giulia, Popoli, Maurizio·2012·Neuropharmacology

Abstract

Half a century after the first formulation of the monoamine hypothesis, compelling evidence implies that long-term changes in an array of brain areas and circuits mediating complex cognitive-emotional behaviors represent the biological underpinnings of mood/anxiety disorders. A large number of clinical studies suggest that pathophysiology is associated with dysfunction of the predominant glutamatergic system, malfunction in the mechanisms regulating clearance and metabolism of glutamate, and cytoarchitectural/morphological maladaptive changes in a number of brain areas mediating cognitive-emotional behaviors. Concurrently, a wealth of data from animal models have shown that different types of environmental stress enhance glutamate release/transmission in limbic/cortical areas and exert powerful structural effects, inducing dendritic remodeling, reduction of synapses and possibly volumetric reductions resembling those observed in depressed patients. Because a vast majority of neurons and synapses in these areas and circuits use glutamate as neurotransmitter, it would be limiting to maintain that glutamate is in some way 'involved' in mood/anxiety disorders; rather it should be recognized that the glutamatergic system is a primary mediator of psychiatric pathology and, potentially, also a final common pathway for the therapeutic action of antidepressant agents. A paradigm shift from a monoamine hypothesis of depression to a neuroplasticity hypothesis focused on glutamate may represent a substantial advancement in the working hypothesis that drives research for new drugs and therapies. Importantly, despite the availability of multiple classes of drugs with monoamine-based mechanisms of action, there remains a large percentage of patients who fail to achieve a sustained remission of depressive symptoms. The unmet need for improved pharmacotherapies for treatment-resistant depression means there is a large space for the development of new compounds with novel mechanisms of action such as glutamate transmission and related pathways. This article is part of a Special Issue entitled 'Anxiety and Depression'.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.neuropharm.2011.07.036

Cites

230 of 230 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Serotonin modulates glutamatergic transmission and might kindle NMDA receptor dependent plasticity.

    “Serotonin modulates glutamatergic transmission and might kindle N-methyl-D-aspartate (NMDA) receptor dependent plasticity (Bennett, 2010;Sanacora et al., 2012).”

    From Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression (2017) · cites this paper as Sanacora et al., 2012

    Section 8.4 reports that acute fluoxetine, a selective serotonin-reuptake inhibitor, increased extracellular glutamate, providing indirect support for a link between serotonergic treatment and glutamatergic transmission. Section 8 says antidepressants affect synaptic plasticity and NMDA-receptor function, but the passages do not establish that serotonin itself kindles NMDA-receptor-dependent plasticity. No page numbers are available in our copy. (LLM, conf=0.78)

    Experimental — accuracy not yet measured
  • The literature proposes three broad disease models for treatment resistance.

    “There are three broad disease models proposed by the literature to explain treatment resistance, summarised in Figure 5 (see eAppendix 3 for search details). 48–51”
  • Glutamatergic neurotransmission is dysregulated in major depressive disorder.

    “There has been suggestion that glutamatergic neurotransmission is dysregulated in MDD.83,84”
  • Stress-induced dysfunction in forebrain excitatory transmission led to the excitatory synaptic transmission hypothesis of depression.

    “Stress-induced dysfunction in forebrain excitatory transmission has led to the development of the excitatory synaptic transmission hypothesis of depression (22, 32, 33).”
  • Antidepressants are believed to exert one of their therapeutic effects by modulating the extracellular availability of glutamate.

    “Interestingly, antidepressants are believed to exert one of the therapeutic effects by modulating the extracellular availability of this neurotransmitter [122,123,124,125].”

    From P2X7 Receptor Signaling in Stress and Depression (2019) · cites this paper as [123]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Sanacora, G., Treccani, G., & Popoli, M.
Affiliations
  • Yale University (US)
  • University of Milan (IT)
Corresponding author
Popoli, Maurizio
Venue
Neuropharmacology
Publisher
Elsevier BV
Published
2012-01
Volume
62
Issue
1
Pages
63-77
ISSN
0028-3908 (ISSN-L)
OpenAlex
W72199885
Cited by
1,036
References
230
Citations by year
2026: 48 · 2025: 61 · 2024: 66 · 2023: 74 · 2022: 80 · 2021: 80 · 2020: 89 · 2019: 67 · 2018: 62 · 2017: 66 · 2016: 83 · 2015: 90 · 2014: 71 · 2013: 55 · 2012: 38
FWCI
6.75
Type
journal article
Language
en
Open access
Locations
  • Neuropharmacology (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institute of Mental Health (R01MH081211, K02MH076222)
Topics
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
depression, glutamate hypothesis, glutamatergic system, monoamine hypothesis, mood disorders, anxiety disorders, environmental stress, dendritic remodeling, synaptic loss, neuroplasticity, antidepressant mechanism, treatment-resistant depression, glutamate metabolism, limbic system
MeSH terms
Animals, Antidepressive Agents, Brain, Drug Evaluation, Preclinical, gamma-Aminobutyric Acid, Glucocorticoids, Humans, Synaptic Transmission, Magnetic Resonance Spectroscopy, Receptors, N-Methyl-D-Aspartate, Glutamic Acid, Mood Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review